Results 221 to 230 of about 1,785,230 (301)
A Rare Cause of Gastrointestinal Bleeding: Taeniasis in a Roux-en-Y Gastric Bypass Patient. [PDF]
Ribeiro Dias R +4 more
europepmc +1 more source
Disease classification criteria and response criteria are important tools in the conduct of observational studies and clinical trials for rheumatic diseases. This paper updates methodologic guidance for classification and response criteria funded, developed and/or endorsed by the American College of Rheumatology (ACR), incorporating contemporary ...
Sindhu R. Johnson +4 more
wiley +1 more source
Atypical Arytenoid Lesion Revealing Lobular Capillary Hemangioma: Diagnostic and Therapeutic Challenges. [PDF]
Bravo Quiroz JG +4 more
europepmc +1 more source
Objective To characterize the clinical, immunologic, and proteomic changes associated with CD19 chimeric antigen receptor T cell therapy in patients with progressive systemic sclerosis (SSc). Methods Patients with progressive SSc received CD19 chimeric antigen receptor (CAR)‐T cell therapy and were observed longitudinally for safety, clinical efficacy,
Chenhan Jia +16 more
wiley +1 more source
Multidisciplinary Management of Paraneoplastic Anti-N-Methyl-D-Aspartate Receptor Encephalitis Associated With Ovarian Teratoma: A Case Report. [PDF]
Meléndez-Fernandez AP +8 more
europepmc +1 more source
Expert Perspectives: Defining and Managing Progressive Pulmonary Fibrosis in Systemic Sclerosis
Systemic sclerosis–associated interstitial lung disease (SSc‐ILD) is one of the leading causes of morbidity and mortality in SSc, affecting up to three‐quarters of patients. The disease course is highly heterogeneous, ranging from indolent, nonprogressive forms to rapidly progressive pulmonary fibrosis (PPF).
Devis Benfaremo +7 more
wiley +1 more source
Autoimmune Disorders and Thrombophilia in Pathologic Pregnancies: Management Throughout the Full Gestation. [PDF]
Gao R, Qin L.
europepmc +1 more source
From Interferon Signature to the Clinical Landscape: Type I Interferonopathies
Background Type I interferonopathies are heterogeneous diseases driven by dysregulated IFN‐I signaling. Diagnosis is challenging due to clinical/molecular variability and the need for IFN‐I quantification. Objective To characterize the clinical, immunological, genetic, molecular profiles of patients with suspected enhanced IFN‐I signaling, and assess ...
Ismail Yaz +13 more
wiley +1 more source

